SOUTH SAN FRANCISCO, Calif., Oct. 25 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE), today announced that Stephen A. Sherwin, M.D., chairman and chief executive officer, and Sharon E. Tetlow, senior vice president and chief financial officer of Cell Genesys, will host a conference call relating to the company's third quarter financial results that will be broadcast live over the internet on Thursday, November 1, 2007, at 2:00 p.m. PT/ 5:00 p.m. ET.
The webcast will be available on the investor relations section of the company's website, http://www.cellgenesys.com. If you are unable to listen to the live webcast, the call will be archived on the website for at least 72 hours following the call. To access the replay, go to the Investor Relations section of the website.
Cell Genesys is focused on the development and commercialization of novel biological therapies for patients with cancer. The company is currently pursuing two clinical stage product platforms -- GVAX(TM) cancer immunotherapies and oncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of GVAX immunotherapy for prostate cancer, Phase 2 trials of GVAX immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial of CG0070 oncolytic virus therapy for bladder cancer. Cell Genesys continues to hold an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. Cell Genesys is headquartered in South San Francisco, CA and has its principal manufacturing operation in Hayward, CA. For additional information, please visit the company's website at http://www.cellgenesys.com.
Statements made herein about the company, other than statements of historical fact, including statements about the company's, progress, results and timing of clinical trials and preclinical programs and the nature of product pipelines are forward-looking statements and are subject to a number of uncertainties that could cause actual results to differ materially from the statements made, including risks associated with the success of clinical trials and research and development programs, the regulatory approval process for clinical trials, competitive technologies and products, patents, continuation of corporate partnerships and the need for additional financings. For information about these and other risks which may affect Cell Genesys, please see the company's Annual Report on Form 10-K for the year ended December 31, 2006 filed on August 7, 2007 as well as Cell Genesys' reports on Form 10-Q and 8-K and other reports filed from time to time with the Securities and Exchange Commission. The company assumes no obligation to update the forward-looking information in this press release.
|SOURCE Cell Genesys, Inc.|
Copyright©2007 PR Newswire.
All rights reserved